BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Choi WH, Lee IA. The Mechanism of Action of Ursolic Acid as a Potential Anti-Toxoplasmosis Agent, and Its Immunomodulatory Effects. Pathogens 2019;8:E61. [PMID: 31075881 DOI: 10.3390/pathogens8020061] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
Number Citing Articles
1 Hermanto F, Subarnas A, Bambang Sutjiatmo A, Berbudi A. MOLECULAR DOCKING STUDY AND PHARMACOPHORE MODELLING OF URSOLIC ACID AS AN ANTIMALARIAL USING STRUCTURE-BASED DRUG DESIGN METHOD. Int J App Pharm 2023. [DOI: 10.22159/ijap.2023v15i1.46298] [Reference Citation Analysis]
2 Panda SS, Thangaraju M, Lokeshwar BL. Ursolic Acid Analogs as Potential Therapeutics for Cancer. Molecules 2022;27. [PMID: 36558113 DOI: 10.3390/molecules27248981] [Reference Citation Analysis]
3 Mioc M, Milan A, Malița D, Mioc A, Prodea A, Racoviceanu R, Ghiulai R, Cristea A, Căruntu F, Șoica C. Recent Advances Regarding the Molecular Mechanisms of Triterpenic Acids: A Review (Part I). IJMS 2022;23:7740. [DOI: 10.3390/ijms23147740] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 8.0] [Reference Citation Analysis]
4 Hajj RE, Tawk L, Itani S, Hamie M, Ezzeddine J, El Sabban M, El Hajj H. Toxoplasmosis: Current and Emerging Parasite Druggable Targets. Microorganisms 2021;9:2531. [DOI: 10.3390/microorganisms9122531] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
5 Zhang J, Chen J, Lv K, Li B, Yan B, Gai L, Shi C, Wang X, Si H, Zhang J. Myrislignan Induces Redox Imbalance and Activates Autophagy in Toxoplasma gondii. Front Cell Infect Microbiol 2021;11:730222. [PMID: 34540720 DOI: 10.3389/fcimb.2021.730222] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
6 Jesus JA, Sousa IMO, da Silva TNF, Ferreira AF, Laurenti MD, Antonangelo L, Faria CS, da Costa PC, de Carvalho Ferreira D, Passero LFD. Preclinical Assessment of Ursolic Acid Loaded into Nanostructured Lipid Carriers in Experimental Visceral Leishmaniasis. Pharmaceutics 2021;13:908. [PMID: 34205283 DOI: 10.3390/pharmaceutics13060908] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
7 Peng F, Zhang H, He X, Song Z. Effects of Ursolic Acid on Intestinal Health and Gut Bacteria Antibiotic Resistance in Mice. Front Physiol 2021;12:650190. [PMID: 34122127 DOI: 10.3389/fphys.2021.650190] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
8 Smith NC, Goulart C, Hayward JA, Kupz A, Miller CM, van Dooren GG. Control of human toxoplasmosis. Int J Parasitol 2021;51:95-121. [PMID: 33347832 DOI: 10.1016/j.ijpara.2020.11.001] [Cited by in Crossref: 32] [Cited by in F6Publishing: 37] [Article Influence: 10.7] [Reference Citation Analysis]
9 Choi WH, Park JS. Immunogenicity and Protective Effect of a Virus-Like Particle Containing the SAG1 Antigen of Toxoplasma gondii as a Potential Vaccine Candidate for Toxoplasmosis. Biomedicines 2020;8:E91. [PMID: 32325746 DOI: 10.3390/biomedicines8040091] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
10 Bilbao-Ramos P, Serrano DR, Ruiz Saldaña HK, Torrado JJ, Bolás-Fernández F, Dea-Ayuela MA. Evaluating the Potential of Ursolic Acid as Bioproduct for Cutaneous and Visceral Leishmaniasis. Molecules 2020;25:E1394. [PMID: 32204358 DOI: 10.3390/molecules25061394] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
11 Deng Y, Wu T, Zhai SQ, Li CH. Recent progress on anti-Toxoplasma drugs discovery: Design, synthesis and screening. Eur J Med Chem 2019;183:111711. [PMID: 31585276 DOI: 10.1016/j.ejmech.2019.111711] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 5.5] [Reference Citation Analysis]